Trial site
Vesalion s.r.o.
Moravska Ostrava A Privoz, 702 00, CzechiaEU-13 widening countryNot linked to an institution yet
- 8running trials
- 5closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 25 trials
- Phase 2/31 trial
- Status
- Active, not recruiting5 trials
- Completed5 trials
- Not yet recruiting3 trials
- Lead sponsor
- Alumis Inc2 trials
- MoonLake Immunotherapeutics AG2 trials
- Acelyrin Inc.1 trial
- Alfasigma S.p.A.1 trial
- Bristol-Myers Squibb1 trial
- and 6 more
Running trials
Not yet recruiting
A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY)
2025-524005-32-00· Phase 2· Elevara Medicines Limited· Source
Not yet recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Not yet recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of PPV-06 Active Immunotherapy in Patients with Inflammatory Knee Osteoarthritis (KOA).
2024-514388-24-00· Phase 2· Peptinov· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462· Phase 2· Immunovant Sciences GmbH· Source
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· Phase 3· Alumis Inc· Source
Active, not recruiting
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
NCT05785611· Phase 3· Alfasigma S.p.A.· Source
Active, not recruiting
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
NCT04908189· Phase 3· Bristol-Myers Squibb· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error